$24.440
-2.251 (-9.21%)Zum Schluss
PBLS-News
PBLS-Events
Parabilis Medicines Stock Rises 6.3% to $29.20
Parabilis Medicines is up 6.3%, or $1.72 to $29.20.
Parabilis Medicines Shares Drop 12.5% to $36.51
Parabilis Medicines is down -12.5%, or -$5.22 to $36.51.
Parabilis Medicines Appoints Craig Tendler to Board of Directors
Parabilis Medicines announced the appointment of Craig Tendler to its board of directors. Tendler has served as a scientific advisor to Parabilis Medicines, a role he will continue alongside his board responsibilities. Tendler brings more than 30 years of experience in oncology drug development and medical affairs, including two decades at Johnson & Johnson, where he most recently served as global head of late-stage clinical development and global medical affairs for oncology. Tendler currently serves on the board of directors of TuHURA Biosciences and Predicta Biosciences and as a scientific advisor for several biotechnology companies. He is also an alternate industry representative to the FDA's Oncologic Drugs Advisory Committee.
Parabilis Medicines Q2 Revenue $148K, Misses Consensus $16.67M
Reports Q2 revenue $148,000, consensus $16.67M. "This quarter marked meaningful progress toward our long-term vision as we continued advancing zolucatetide across multiple Wnt/beta-catenin-driven diseases, including toward planned registrational development in desmoid tumors, while also extending the reach of our Helicon(TM) platform through our strategic research collaboration with Regeneron focused on developing Antibody-Helicon Conjugates," said Mathai Mammen, M.D., Ph.D., Chairman, President and Chief Executive Officer of Parabilis Medicines.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.